Oncogenic FGFR1 mutation and amplification in common cellular origin in a composite tumor with neuroblastoma and pheochromocytoma

Cancer Sci. 2022 Apr;113(4):1535-1541. doi: 10.1111/cas.15260. Epub 2022 Feb 16.

Abstract

Neuroblastoma (NB) and pheochromocytoma (PCC) are derived from neural crest cells (NCCs); however, composite tumors with NB and PCC are rare, and their underlying molecular mechanisms remain unknown. To address this issue, we performed exome and transcriptome sequencing with formalin-fixed paraffin-embedded (FFPE) samples from the NB, PCC, and mixed lesions in a patient with a composite tumor. Whole-exome sequencing revealed that most mutations (80%) were shared by all samples, indicating that NB and PCC evolved from the same clone. Notably, all samples harbored both mutation and focal amplification in the FGFR1 oncogene, resulting in an extraordinarily high expression, likely to be the main driver of this tumor. Transcriptome sequencing revealed undifferentiated expression profiles for the NB lesions. Considering that a metastatic lesion was also composite, most likely, the primitive founding lesions should differentiate into both NB and PCC. This is the first reported case with composite-NB and PCC genetically proven to harbor an oncogenic FGFR1 alteration of a common cellular origin.

Keywords: FGFR1; common cellular origin; composite tumor; neuroblastoma; pheochromocytoma.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Gland Neoplasms* / genetics
  • Adrenal Gland Neoplasms* / pathology
  • Humans
  • Mutation
  • Neuroblastoma* / genetics
  • Neuroblastoma* / pathology
  • Oncogenes
  • Pheochromocytoma* / genetics
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics

Substances

  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1